News & Events
All the latest news and events from PhoreMost
4th November 2019
PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development
Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announced an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor, through preclinical dev …
